Skip to main content
SpringerLink
Log in

Major Nano-based Products: Nanomedicine, Nanosensors, and Nanodiagnostics

  • Chapter
  • First Online:
Applications of Nanomaterials in Human Health

Abstract

Nanomedicine is a very rapidly evolving field which has many biological, biomedical, and healthcare applications. Due to various beneficial properties of the nanomaterials, such as vast surface area, high biocompatibility, and biodistribution properties, these nanoparticles have been used to develop many useful products. Many of these nano-based products are under various developmental stages and many nanodrugs have been reported to have entered clinical phases of testing for various treatment conditions. In this chapter, we discuss some of the major nanoproducts which are developed for the treatment, diagnosis, and biosensing purposes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ahn HK, Jung M, Sym SJ et al (2014) A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non–small-cell lung cancer. Cancer Chemother Pharmacol 74:277–282

    CAS  Google Scholar 

  • Awada A, Garcia AA, Chan S et al (2013) Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol 14(12):1216–1225

    CAS  Google Scholar 

  • Bansal S, Bansal M, Kumria R (2012) Nanocrystals: current strategies and trends. Int J Res Pharm Biomed Sci 3:406–419

    Google Scholar 

  • Bobo D, Robinson KJ, Islam J et al (2016) Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res 33(10):2373–2387

    CAS  Google Scholar 

  • Bruchez M Jr, Moronne M, Gin P et al (1998) Semiconductor nanocrystals as fluorescent biological labels. Science 281:2013–2016

    CAS  Google Scholar 

  • Caster JM, Patel AN, Zhang T, Wang A (2017) Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol 9(1). https://doi.org/10.1002/wnan

  • Centerwatch (n.d.) 2017 FDA approved drugs. Available at: www.center-watch.com/drug-information/fda-approved-drugs. Accessed 25 Oct 2017

  • Clancy JP, Dupont L, Konstan MW et al (2013) Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 68:818–825

    CAS  Google Scholar 

  • ClinicalTrials.gov (n.d.). Available at: https://clinicaltrials.gov. Accessed 25 Oct 2017

  • Cohen CR, Brown J, Moscicki AB et al (2011) A phase 1 randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel) in healthy young women administered twice daily for 14 days. PLoS One 6(1):e16258

    CAS  Google Scholar 

  • Cortes JE, Goldberg SL, Feldman EJ et al (2015) Phase II, multicenter, randomized trial of CPX-351 (cytarabine: daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer 121:234–242

    CAS  Google Scholar 

  • Desai N, Trieu V, Yao ZW et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res 12(4):1317–1324

    CAS  Google Scholar 

  • Dipetrillo T, Milas L, Evans D et al (2006) Paclitaxel poliglumex (PPXXyotax) and concurrent radiation for esophageal and gastric cancer: a phase 1 study. Am J Clin Oncol 29:376–379

    Google Scholar 

  • Dipetrillo T, Suntharalingam M, Ng T et al (2012) Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial. Am J Clin Oncol 35:64–67

    CAS  Google Scholar 

  • Elamanchili P, Diwan M, Cao M, Samuel J (2004) Characterization of poly(D, L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22:2406–2412

    CAS  Google Scholar 

  • Fleischman T (2016) Cancer killers: C dots show ability to induce cell death in tumors. Cornell Chronicle. 26 Sep 2016. Available at: http://news.cornell.edu/stories/2016/09/cancer-killers-c-dots-show-ability-induce-cell-death-tumors. Accessed 9 Aug 2017

  • Flexion Therapeutics, Inc (n.d.) Our product: Zilretta (triamcinolone acetonide extended release formulation). Available at: https://flexiontherapeutics.com/our-product. Accessed 25 Oct 2017

  • Food and Drug Administration (2017) Novel drug approvals for 2017. 25 Oct 2017. Available at: www.fda.gov/drugs/developmentapprovalprocess/druginnovation/ucm537040. Accessed 25 Oct 2017

  • Foss F (2006) Clinical experience with denileukin diftitox (Ontak). Semin Oncol 33(1 Suppl 3):S11–S16

    CAS  Google Scholar 

  • Fuentes AC, Szwed E, Spears CD et al (2015) Denileukin diftitox (Ontak) as maintenance therapy for peripheral T-cell lymphomas: three cases with sustained remission. Case Pep Oncol Med 2015:123756. https://doi.org/10.1155/2015/123756

    Article  Google Scholar 

  • Gabizon A, Catane R, Uziely B et al (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol-coated liposomes. Cancer Res 54(4):987–992

    CAS  Google Scholar 

  • Gao L, Liu G, Ma J et al (2013) Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs. Pharm Res 30:307–324

    CAS  Google Scholar 

  • Geho WB, Geho HC, Lau JR, Gana TJ (2009) Hepatic directed vesicle insulin: a review of formulation development and preclinical evaluation. J Diabetes Sci Technol 3:1451–1459

    Google Scholar 

  • Geho WB, Rosenberg LN, Schwartz SL et al (2014) A single-blind, placebo-controlled, dose ranging trial of oral hepatic-directed vesicle insulin add-on to oral antidiabetic treatment in patients with type 2 diabetes mellitus. J Diabetes Sci Technol 8:551–559

    CAS  Google Scholar 

  • Glenn GM, Fries LF, Smith G et al (2015) Modeling maternal fetal RSV F vaccine induced antibody transfer in Guinea pigs. Vaccine 33:6488–6492

    CAS  Google Scholar 

  • Gregory AE, Titball R, Williamson D (2013) Vaccine delivery using nanoparticles. Front Cell Infect Microbiol 3:13

    Google Scholar 

  • Havel HA (2016) Where are the nanodrugs? An industry perspective on development of drug products containing nanomaterials. AAPS J 18(6):1351–1353

    CAS  Google Scholar 

  • Havel H, Finch G, Strode P et al (2016) Nanomedicines: from bench to bedside and beyond. AAPS J 18(6):1373–1378

    CAS  Google Scholar 

  • Hu X, Miller L, Richman S et al (2012) A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol 52(6):798–808

    CAS  Google Scholar 

  • Jeyapalan S, Boxerman J, Donahue J et al (2014) Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group study. Am J Clin Oncol 37:444–449

    CAS  Google Scholar 

  • Kim TY, Kim DW, Chung JY et al (2004) Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10:3708–3716

    CAS  Google Scholar 

  • Kim DW, Kim SY, Kim HK et al (2007) Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non–small-cell lung cancer. Ann Oncol 18:2009–2014

    Google Scholar 

  • Lancet JE, Cortes JE, Hogge DE et al (2014) Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs. cytarabine/daunorubicin in older adults with untreated AML. Blood 123:3239–3246

    CAS  Google Scholar 

  • Lee KS, Chung HC, Im SA et al (2008) Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 108:241–250

    CAS  Google Scholar 

  • Libutti SK, Paciotti GF, Byrnes AA et al (2010) Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 16:6139–6149

    CAS  Google Scholar 

  • Maier-Hauff K, Ulrich F, Nestler D et al (2011) Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neuro-Oncol 103(2):317–324

    Google Scholar 

  • Morgan MA, Darcy KM, Rose PG et al (2008) Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal, or fallopian tube cancer: a phase 1 and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol 110:329–335

    CAS  Google Scholar 

  • O’Loughlin J, Millwood IY, McDonald HM et al (2010) Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase 1 study. Sex Transm Dis 37:100–104

    Google Scholar 

  • Ortega A, Farah S, Tranque P et al (2015) Antimicrobial evaluation of quaternary ammonium polyethyleneimine nanoparticles against clinical isolates of pathogenic bacteria. IET Nanobiotechnol 9:342–348

    Google Scholar 

  • Price CF, Tyssen D, Sonza S et al (2011) SPL7013 Gel (VivaGel) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS One 6(9):e24095

    CAS  Google Scholar 

  • Sabbatini P, Sill MW, O’Malley D et al (2008) A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group study. Gynecol Oncol 111(3):455–460

    CAS  Google Scholar 

  • Stanberry LR, Simon JK, Johnson C et al (2012) Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens. Vaccine 30:307–316

    CAS  Google Scholar 

  • Svenson S, Tomalia DA (2005) Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev 57:2106–2129

    CAS  Google Scholar 

  • Valle JW, Armstrong A, Newman C et al (2011) A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Investig New Drugs 29:1029–1037

    CAS  Google Scholar 

  • Ventola CL (2012a) The nanomedicine revolution: part 1: emerging concepts. P T 37(9):512–525

    Google Scholar 

  • Ventola CL (2012b) The nanomedicine revolution: part 2: current and future clinical applications. P T 37(10):582–591

    Google Scholar 

  • Ventola CL (2017) Progress in nanomedicine: approved and investigational nanodrugs. P T 42(12):742–755

    Google Scholar 

  • Verschraegen CF, Skubitz K, Daud A et al (2009) A phase 1 and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol 63:903–910

    CAS  Google Scholar 

  • Weiss GJ, Chao J, Neidhart JD et al (2013) First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Investig New Drugs 31:986–1000

    CAS  Google Scholar 

  • Weissig V, Pettinger TK, Murdock N (2015) Nanopharmaceuticals (part 1): products on the market. Int J Nanomedicine 10:1245–1257

    CAS  Google Scholar 

  • Wolfram J, Zhu M, Yang Y et al (2015) Safety of nanoparticles in medicine. Curr Drug Targets 16(14):1671–1681

    CAS  Google Scholar 

  • Zhu M, Wang R, Nie G (2014) Applications of nanomaterials as vaccine adjuvants. Hum Vaccin Immunother 10:2761–2774

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Stem Cell Biology, Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

    Firdos Alam Khan

Authors
  1. Firdos Alam Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Firdos Alam Khan .

Editor information

Editors and Affiliations

  1. Department of Stem Cell Biology, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

    Firdos Alam Khan

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Khan, F.A. (2020). Major Nano-based Products: Nanomedicine, Nanosensors, and Nanodiagnostics. In: Khan, F. (eds) Applications of Nanomaterials in Human Health. Springer, Singapore. https://doi.org/10.1007/978-981-15-4802-4_11

Download citation

Publish with us

Policies and ethics

Search

Navigation